Overview
NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating and preventing influenza in children 1 to 11 years. This is because the company did not provide an evidence submission.
Last reviewed: 19 February 2026
Next review: We will review this decision if the company decides to make a submission.